{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":".035","upperLimit":".152","value":".080"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"100"}],"units":"Participants"}],"description":"The proportion of FAS subjects with one or more NIR fluorescence positive cancerous synchronous lesions not detected under normal light and/or palpation","dispersionType":"95% Confidence Interval","groups":[{"description":"The full analysis set will include subjects exposed to OTL38 and randomized to undergo NIR fluorescent imaging (OTL38+Imaging) who were evaluated under both normal light and NIR fluorescent light imaging","id":"OG000","title":"Fully Analysis Set (FAS)"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): The FAS for the primary analysis of the primary efficacy endpoint will include subjects exposed to OTL38 and randomized to undergo fluorescent imaging (OTL38+Imaging) who:\n\n• Were evaluated under both normal light/palpation and NIR fluorescent light imaging","reportingStatus":"POSTED","timeFrame":"1 day","title":"Identification of Cancerous Synchronous Lesions","type":"PRIMARY","unitOfMeasure":"proportion of participants"}